Takeda Pharmaceuticals Co. Ltd. will collaborate with Stanford University to form the Stanford Alliance for Innovative Medicines (Stanford AIM) to transform novel Stanford research into next-generation treatments for diseases.
The partnership will allow the organizations to identify projects that can help accelerate the process of bringing therapeutic drugs to market, therefore serving patients’ needs. Stanford AIM will encourage academic and industry scientists to collaborate on new medicines that will be meaningful for patients.
“Takeda’s alliance with Stanford demonstrates our commitment to advancing medicines as quickly and efficiently as possible – from drug discovery to development and ultimately to patients,” Juan Harrison, Takeda's vice president and head of Strategic Academic Alliances, said. “We look forward to combining the intellectual capital of Takeda and Stanford scientists, motivating both to come together as peers, in order to deliver medicines that represent real and meaningful benefits for patients.”
Takeda, a global pharmaceutical company, focuses on translating science into life-changing medicines. Specifically, the company specializes in oncology, gastroenterology and central nervous system therapeutic areas plus vaccines.